

PRESS CLIPPING SHEET

PUBLICATION:	Egyptian Gazette
DATE:	20-December-2015
COUNTRY:	Egypt
CIRCULATION:	60,000
TITLE :	BI Will Invest 11b Euros in R&D in the Next 5 Years
PAGE:	05
ARTICLE TYPE:	Health Corporate News
REPORTER:	Amina Abdul Salam

BI will invest 11b euros in R&D in the next 5 years

BOEHRINGER Ingelheim is launching a new research and development (R&D) strategy and a five-year R&D investment programme. This new plan was announced at its R&D press conference in Berlin. The company pledges to invest a total of 11 billion euros in its new R&D programme over the next five years. Of the total investment, 5 billion euros will go to preclinical R&D with 1.5 billion euros thereof planned for collaborations with external partners. The company is aiming to develop the next generation of medical breakthroughs and maintain its excellent competitive position. The new R&D strategy embraces open innovation in the form of external collaborations to better leverage emerging science and Boehringer Ingelheim's experience and capabilities for the discovery of new medicines.

"With eleven new launches in 2014 and 2015, our R&D



Dr Michel Pairet

organisation is an example of Boehringer Ingelheim's outstanding capability in this field and is important for our region as we focus even more on diabetes and oncology," said Professor Dr Mohammad Meshref, Medical Director, Boehringer Ingelheim, META. "The new programme and strategy reflect our corporate philosophy of long-term, sustainable growth. They will enable us to continue our excellent track record of bringing therapeutic innovations with high value for patients to the market."

"Our new strategy embraces the trend towards more extensive open-innovation approaches between academia and industry in biomedical research. Our partners benefit by accessing our broad experience and capabilities and through establishment of long-term personal interactions with our R&D teams," explained Dr Michel Pairet, senior corporate vice president research and non-clinical development at Boehringer Ingelheim and designated member of the Board of Managing Directors from January 2016 onwards. The new strategy will foster our external collaboration efforts by enabling us to be faster and more flexible. This is of essence for research beyond the borders of our current focus areas, where we explore emerging science, new indications and new technology to expand opportunities."

The new R&D strategy is an important building block of Boehringer Ingelheim's global strategy to be prepared for chances and challenges in the pharmaceutical market.